HighGravityDataBioMarin Pharmaceutical — May 4, 2026 release
Fiscal 2026 first-quarter results · 8-K Item 2.02 · Exhibit 99.1 · 0001048477-26-000006
Showing in the filing
PALYNZIQ Revenue
“expected to increase year-over-year”
Period
FY2026
Measure
GAAP-tied
Source
Prose
All guidance in this release · 14
Total Revenues (Full-Year) for FY2026
“between $3.825 billion and $3.925 billion”
Total Revenues Growth Rate (Y/Y, at Midpoint) for FY2026
“20%”
PALYNZIQ Revenue for FY2026
“expected to increase year-over-year”
Amicus Acquisition Impact on Non-GAAP Dilute… for FY2026
“slightly dilutive”
Non-GAAP Diluted EPS Recognized in Second Ha… for H2 FY2026
“approximately two-thirds”
Total Revenues Expected in Second Half of 2026 for H2 FY2026
“more than 55%”
Non-GAAP Diluted EPS (Q2 vs Q1) for Q2 FY2026
“modestly higher than in Q1”
Total Revenues for FY2026
“$3,825 to $3,925”
Enzyme Therapies for FY2026
“$2,725 to $2,775”
VOXZOGO for FY2026
“$975 to $1,025”
Other Revenues for FY2026
“$100 to $125”
Non-GAAP Diluted EPS for FY2026
“$4.85 to $5.05”
Non-GAAP Diluted EPS - Weighted-Average Dilu… for FY2026
“approximately 200 million”
Non-GAAP Diluted EPS - combined company tax … for FY2026
“22%”
Exhibit 99.1 · the passage around this item
… earlier in the release
Continued underlying patient demand in Q1 for PALYNZIQ was driven by an increase in enrollments and new starts in the under-18-year age group following label expansion in February. PALYNZIQ revenue is expected to increase over time with continued patient demand and as new adult and adolescent patients titrate up to maintenance dosing. As a result, full-year 2026 PALYNZIQ revenue is expected to increase year-over-year. • The number of children being treated with VOXZOGO increased by more than 20% Y/Y in the first quarter. As expected, large VOXZOGO orders in fourth quarter of 2025 resulted in modest Y/Y growth of 3% in the first quarter of 2026. Value Commitment • During the first quarter, the company secured financing of approximately $3.7 billion of non-convertible debt to support the Amicus acquisition, achieving favorable pricing across the capital structure. • BioMarin generated operating cash flows totaling $221 million in first quarter 2026. Total cash was approximately $2 billion as of the end of the quarter, and continued increasing operating cash flow is expected to support sustained investment in innovation and future growth. First Quarter 2026 Financial Highlights • Total Revenues for the first quarter of 2026 were $766 million, an increase of $21 million compared to the same period in 2025, primarily driven by timing of large government orders outside the U.S. and increase in patient demand for Enzyme Therapies (ALDURAZYME ® , BRINEURA, NAGLAZYME, PALYNZIQ and VIMIZIM) as well as new patients initiating VOXZOGO therapy across all regions. The increase was partially offset by lower
later in the release …
the item shown at left
other guidance in this release
Text is the filed exhibit, verbatim.